Cargando…
Bioinformatics-based identification of miR-542-5p as a predictive biomarker in breast cancer therapy
BACKGROUND: Tamoxifen is the first-line hormone therapy for estrogen receptor alpha positive (ERα+) breast cancer. However, about 40% of patients with ERα + breast cancer who receive tamoxifen therapy eventually develop resistance resulting in a poor prognosis. The aim of this study was to mine avai...
Autores principales: | Zhu, Qiong-Ni, Renaud, Helen, Guo, Ying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769523/ https://www.ncbi.nlm.nih.gov/pubmed/29371858 http://dx.doi.org/10.1186/s41065-018-0055-7 |
Ejemplares similares
-
MiR-542-5p Inhibits Hyperglycemia and Hyperlipoidemia by Targeting FOXO1 in the Liver
por: Tian, Fang, et al.
Publicado: (2020) -
Pristimerin Suppressed Breast Cancer Progression via miR-542-5p/DUB3 Axis
por: Cheng, Shihuan, et al.
Publicado: (2020) -
Expression of miR-542-3p in osteosarcoma with miRNA microarray data, and its potential signaling pathways
por: Li, Zhen, et al.
Publicado: (2019) -
miR-542-5p Attenuates Fibroblast Activation by Targeting Integrin α6 in Silica-Induced Pulmonary Fibrosis
por: Yuan, Jiali, et al.
Publicado: (2018) -
MicroRNAs miR-19, miR-340, miR-374 and miR-542 regulate MID1 protein expression
por: Unterbruner, Kristoffer, et al.
Publicado: (2018)